The Fifth People's Hospital of Shanghai
Shanghai, Shanghai Municipality, 200240, China
Completed
NCT Number: NCT06428110
A Prospective Cohort Study on Warfarin Personalized Medication
Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.
Completed
Looking for future studies?
Notify MeKey information
Age range
65 year–100 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.
- Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.
- Signing an informed consent form before blood sample collection.
Exclusion criteria
- Patients who are allergic to warfarin or lactose.
- Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.
- Patients with bleeding tendencies, blood disorders with platelet counts > 400 × 10^9 /L or < 100 × 10^9 /L, hemoglobin > 169 or < 100 g/L.
- History of peptic ulcer disease.
- Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.
- Neurological disorders such as epilepsy.
Treatment and study plan
Primary outcomes
-
Numbers of patients with bleeding events
Time frame: 1 year during the follow-up
Numbers of patients with bleeding events during warfarin treatment
Sponsors and collaborators
Lead sponsor
Haobin Li
Other
Registry information
Official study title
Personalized Medication Research of Warfarin Based on Vascular Aging Assessment
Important dates
- Study start
- 2021
- Primary completion
- 2023
- Study completion
- 2023
- First posted
- May 24, 2024
- Registry last updated
- May 29, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.